<code id='0BC0C8B97C'></code><style id='0BC0C8B97C'></style>
    • <acronym id='0BC0C8B97C'></acronym>
      <center id='0BC0C8B97C'><center id='0BC0C8B97C'><tfoot id='0BC0C8B97C'></tfoot></center><abbr id='0BC0C8B97C'><dir id='0BC0C8B97C'><tfoot id='0BC0C8B97C'></tfoot><noframes id='0BC0C8B97C'>

    • <optgroup id='0BC0C8B97C'><strike id='0BC0C8B97C'><sup id='0BC0C8B97C'></sup></strike><code id='0BC0C8B97C'></code></optgroup>
        1. <b id='0BC0C8B97C'><label id='0BC0C8B97C'><select id='0BC0C8B97C'><dt id='0BC0C8B97C'><span id='0BC0C8B97C'></span></dt></select></label></b><u id='0BC0C8B97C'></u>
          <i id='0BC0C8B97C'><strike id='0BC0C8B97C'><tt id='0BC0C8B97C'><pre id='0BC0C8B97C'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:comprehensive    Page View:12
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In